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Abstract
Background: The Micra transcatheter pacing system (TPS) is a miniaturized, single-chamber pace-
maker system. Study reported herein is an initial experience with implantation of the Micra TPS.
Methods: The leadless pacemaker was implanted in 10 patients with standard indications for a per-
manent pacemaker implantation. All hospitalization costs were calculated for all patients. 
Results: The mean age of the patients was 75 ± 7.1 years, 6 were men and 4 were women. Four 
patients had permanent atrial fibrillation as the basal rhythm and 6 patients had sinus rhythm. All 
patients had at least one relative contraindication that precluded the use of a traditional pacing system. 
Mean intraoperative ventricular sensing amplitude was 10.6 ± 5.4 mV, impedance 843 ± 185 ohms, 
and pacing threshold at 0.24 ms was 0.56 ± 0.23 V. At discharge, those values were 13.9 ± 5.6 mV, 667 
± 119 ohms and 0.47 ± 0.17, respectively. The mean duration of implantation procedure was 82 min, 
while mean fluoroscopy time was 3.5 min. Two patients developed hematoma at the groin puncture site 
post-implantation. In 1 case there was a need for erythrocyte mass transfusion and surgical interven-
tion. Mean total time of hospitalization was 26 days and time from procedure to discharge 12 days. 
Average cost of hospitalization per 1 patient was 11,260.15 EUR minimal cost was 9,052.68 EUR, 
while maximal cost was 16,533.18 EUR.
Conclusions: Implantation of leadless pacemakers is feasible, safe and provides advantages over the 
conventional system. Hospitalization costs vary for individual patients in wide range. (Cardiol J XXX; 
XX, X: xx–xx)
Key words: leadless pacemakers, complications, procedure cost, hospitalization cost
Introduction
Recent advances in miniaturization technolo-
gies and battery chemistries have made it possible 
to develop a pacemaker small enough to implant 
within the heart while still aiming to provide similar 
effectiveness and durability to conventional pace-
makers. The Micra transcatheter pacing system 
(Micra TPS) (Medtronic, USA) is a miniaturized 
single-chamber pacemaker system that is im-
planted directly to the right ventricle, eliminating 
the need for device pocket creation or insertion of 
a pacing lead, thereby avoiding some of the compli-
cations associated with traditional pacing systems 
1www.cardiologyjournal.org
CLINICAL CARDIOLOGY
Cardiology Journal 
XXXX, Vol. XX, No. X, X–X
DOI: 10.5603/CJ.a2018.0075 
Copyright © 2018 Via Medica
ISSN 1897–5593ORIGINAL ARTICLE
[1, 2]. This emerging technology has the potential 
to significantly improve outcomes associated with 
a need for long-term pacing and can help patients 
get back to work and limit disability or restrictions 
to lifestyle [3, 4].
In the present single-center observational 
study, an initial experience with implantation of 
the Micra TPS is reported.
Methods
Procedure
The Micra TPS is a single chamber ventricular 
pacemaker. The device is attached to a steerable 
catheter delivery system with catheter and is 
inserted through a femoral vein with the use of 
a 23-French (outer diameter 27 F) introducer 
sheath. The delivery system is advanced into the 
right ventricle (RV), and the device is affixed to 
the myocardium with four electrically inactive 
nitinol tines located at the distal end of the device. 
If optimal electrical measurement results are not 
achieved the system is fully repositionable while 
the device is still connected to the delivery system. 
After verification of adequate electrical parameters 
and device fixation to the endocardium the device is 
released and delivery system is removed. According 
to this local strategy vascular access site was closed 
with subcutaneous absorbable double ‘figure-of-
eight’ suture followed by 4 h bandage compression 
used for the access site in the groin [5].
Duration of procedure (from femoral vein 
puncture to venous access closure), fluoroscopy 
time, number of device repositions, periprocedural 
electrical measurements (sensing, threshold and 
impedance) and in-hospital adverse events related 
to procedure were evaluated.
Patients
All patients had classic indications for per-
manent pacing system implantation. Patients 
with sinus rhythm were not excluded if they had 
relative or absolute contraindication to traditional 
pacemaker implantation. Prior to procedure pa-
tients and their family members were informed of 
the characteristics of the new system, indications 
and potential complications. Informed consent was 
obtained.
Costs of hospitalization analysis
All costs of hospitalization were calculated 
and summed up for each patient. Costs were di-
vided into following categories: Micra TPS device, 
medical materials excluding Micra TPS (disposable 
materials related to the procedure, pacemaker 
introducer), pharmaceuticals (e.g. oral drugs, 
antibiotics, disinfectants, analgesics), operating 
theatre staff (e.g. electrophysiologists, scrub nurse, 
personal costs of analgesia), cardiology depart-
ment staff (e.g. cardiologists, nurses), additional 
laboratory tests (e.g. blood group, morphology, 
electrolytes, C-reactive protein, procalcitonin, 
natriuretic peptides, viral antigens and antibod-
ies, clotting), additional non-laboratory tests (e.g. 
echocardiography, X-ray), additional non-medical 
costs (e.g. materials and energy, linen, maintenance 
materials, office supplies, informatics and infor-
mation technology, laboratory reagents, medical 
gases, electricity, heat, water, permanent foreign 
services, minor repair of hardware, postage and 
telephone charges — non-medical indirect costs, 
management). 
Results
Baseline characteristics 
The Micra TPS implantation was attempted in 
10 patients with 100% success rate. All patients 
had standard indication for a permanent pacemaker 
implantation, i.e. third-degree atrioventricular 
block (40%), second-degree atrioventricular block 
(30%), symptomatic sick sinus syndrome (20%), 
bradycardia-tachycardia syndrome (10%). The 
mean age of patients was 75 ± 7.6 years, 6 were 
men and 4 were women. Four patients had per-
manent atrial fibrillation (AF) as basal rhythm and 
4 patients had paroxysmal AF or atrial flutter. Over 
half of the patients had a previously implanted car-
diac electronic device including cardiac resynchro-
nization therapy. In addition, all patients had at least 
one condition that precluded the use of a traditional 
pacing system, i.e. history of implantable cardiac 
electronic device (ICED) related infection (60%), 
lack of vascular access on one site and the need to 
preserve venous system for hemodialysis on oppo-
site site (20%) and post mastectomy bilateral upper 
limb lymphedema (10%). Patien characteristics and 
basic procedural data are summarized in Table 1.
Procedure
All the devices were implanted through the 
right femoral vein to the septum of RV. In 50% of 
patient there was no need for any repositioning of 
the system and the position of the device had to 
be changed ≥ 2 times only in 2 patients due to sub-
optimal pacing threshold or sensing value. Mean 
procedure time in the present population was 82 
min (from femoral vein puncture to vascular sheath 
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removal) and mean fluoroscopy duration was 3.5 
min. Mean procedure (from introducer insertion 
to introducer removal) and fluoroscopy time in 
post-approval registry was 34.8 min and 8.9 min, 
respectively.
The mean intraoperative sensing value was 
10.6 ± 5.4 mV and the impedance was 843 ± 185 
ohms. At discharge from hospital, those values 
were 13.9 ± 5.6 mV and 667 ± 119 ohms, respec-
tively. The recommended pacing threshold value, 
i.e. ≤ 1 V at 0.24 ms was achieved in all patients. 
Mean procedure duration was 82 min (55–90 min), 
while mean fluoroscopy time was 3.5 min (minimal 
1’50’’ – maximal 9’09’’). 
Mean total time of hospitalization was 26 days 
(5–60 days) and time from procedure to discharge 
12 days (3–21 days). During post-implantation 
period 2 (20%) patients developed hematoma at 
the groin puncture site. In 1 case there was a 
need for erythrocyte mass transfusion and sur-
gical intervention. The second one was treated 
conservatively without any sequelae.
Adverse events 
Two patients developed groin hematoma. The 
first patient developed large hematoma that was 
associated with anemization, required blood trans-
fusion (6 units of blood) and surgical intervention. 
The second patient complained of groin pain. 
Ultrasound imaging revealed relatively small 
hematoma that was absorbed spontaneously. What 
should be underlined, both patients had a history 
of valve replacement (mechanical aortic prosthesis 
in 1st case, mechanical aortic and mitral valve in 
2nd case) and were under bridging anticoagulant 
therapy (low molecular weight heparin). In patients 
receiving vitamin K antagonists (VKA), treatment 
was continued until the international normalization 
rate was therapeutic (range of 2–3) and in patients 
on non-VKA, treatment discontinued at least 24 h 
before operation.
Costs of hospitalization analysis
Real costs of hospitalization for every patient 
are presented in Table 1. Average cost of hospitali-
zation per 1 patient was 11,260.15 EUR (minimal 
= 9 051.68 EUR and maximal = 16,533.18 EUR). 
Average costs for each category were as follows: 
8,267.66 EUR for medical materials; 54.58 EUR for 
pharmaceuticals; 174.5 EUR for operating theatre 
staff; 1,619.12 EUR (minimal = 303.73 EUR and 
maximal = 3,471.28 EUR) for cardiology depart-
ment staff; 269.26 EUR (minimal = 67.38 EUR and 
maximal = 827.38 EUR) for laboratory additional 
test, 160.71 EUR for non-laboratory additional 
test; 492.69 EUR for additional non-medical costs.
Discussion
Elimination of leads and pocket with the intro-
duction of leadless pacemakers offered potential 
advantages over conventional transvenous sys-
tems. Lead- and pocket-related complications are 
dominant adverse events associated with cardiac 
pacing [1, 2]. Pacing leads and the pacemaker as a 
high-volume foreign body become the background 
for CIED related infections that are associated 
with poor prognosis despite complete hardware 
removal [6, 7]. Micra’s small size, reduced surface 
area, and lack of lead exposed to the bloodstream 
appear to substantially mitigate the risk of early 
device infection [8]. Over the long-term follow-up, 
these features will also promote complete device 
encapsulation, which may significantly reduce the 
risk of late infections.
Micra TPS is a full capability VVIR pacemaker. 
Typical indications for this system include patients 
with atrioventricular conduction disturbances and 
permanent AF. Despite that fact more and more 
patients are offered with the leadless system 
because of conditions that precludes implanta-
tion of conventional pacemaker such as history or 
high risk of infection, lack of axillary/subclavian 
vascular access, thrombosis or need to preserve 
the venous system for hemodialysis. This group of 
patients amounted 6.2% in Investigational Device 
Exemption (IDE) study and reached 20.9% in post-
approval registry [9, 10]. In our cohort all patients, 
had at least one factor that precluded implantation 
of transvenous pacing system.
An early report of Micra TPS implantations 
showed very high procedural success rate of 100% 
[3]. It was reduced to 99.2% in a full cohort of 
patients in the IDE study [9]. The interim report 
from Micra TPS post-approval registry also showed 
high procedural efficacy with 99.6% successful 
implantations [10]. All 10 implantation attempts 
were completed in this study. All the devices were 
able to be implanted to the RV septum, which was 
confirmed in all patients in LAO projection with 
contrast medium injection. Septal positioning of 
the system seems to bring some benefits in terms 
of avoiding pericardial effusion and tamponade. 
In the literature a trend toward more frequent 
septal implantations could be observed. There 
were 65.9% apical implantations in the IDE study 
compared to 39.3% in post-approval registry [8, 9]. 
A similar trend could be observed with a different 
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transcatheter pacemaker, Nanostim (apical position 
in primary analysis cohort vs. total cohort, 48.4% 
vs. 38.1%, respectively) [11].
Although the purpose of each case was a RV 
septal pacing, it did not translate to significantly 
longer procedure duration and/or fluoroscopy 
time. Recommended electrical parameters in 9 
patients were achieved. In 1 patient (patient no. 
7) after two repositions of the system the proce-
dure was ended with sensing value slightly lower 
than recommended, i.e. 4.7 mV. In accordance to 
observations from the trials and registry the value 
increased and reached 9.6 mV before hospital dis-
charge [9, 10, 12].
Nevertheless leadless pacing reduces the rate 
of some procedural and long-term complications 
it also brings new problems that were not present 
with traditional pacing systems, i.e. vascular com-
plications at the groin puncture site. In the IDE 
study arteriovenous fistula or pseudoaneurysm 
occurred in 5 (0.7%) patients [8]. A similar rate 
of vascular complications was observed in post-
approval registry. Among total 0.75% of access site 
complications, there were 2 hematomas (0.25% 
of patients) [9]. Currently there is no data about 
proper periprocedural antithrombotic management 
in those patients.
Although implantation of single chamber VVI 
pacemaker is on the list of guaranteed services but 
total cost of Micra TPS highly exceeds reimburse-
ment level for this category, so individual financing 
was implemented for each patient and this study 
depicts expenditures divided into a range of catego-
ries. According to available research this is the first 
cost analysis of the Micra implantation procedure. 
Hospitalization costs for individual patient with a 
wide range of medical conditions. The price of the 
Micra device was the same for all procedures, but 
final costs varied depending on patient. Those who 
had an infection or an implanted device extraction 
had higher expenditures than those with simple/
stand alone Micra implantation procedure. Two 
patients had bleeding complications. One patient 
had pseudoaneurysm in the vascular access site, 
while the other had femoral artery aneurysm 
demanding intervention. These events prolonged 
hospitalization length and therefore final costs. The 
relatively low cost of operating theatre staff also 
deserves comment. This is due to the fact that the 
hospital calculates it from the staff costs based on 
the hourly wage rates, that, while calculating the 
actual time of treatment, gives very small amounts 
and does not take into account the time between 
procedures. In addition, current analysis did not 
include costs of proctors presence during first 6 
procedures. According to the hospital contract 
these costs were covered by the device supplier.
Limitations of the study
The cost of Micra implantation varies dramati-
cally between centers, contracts with the vendor, 
and country which limits the generalizability of 
this report. However, the primary objective of 
this study was to compare hospital costs between 
patients with different clinical profiles assuming 
one price of the device, mainly due to the fact that 
Poland is applying for Micra implantation reim-
bursement. Therefore a comparison was not made 
with a matched group undergoing transvenous 
pacemaker implantation, because the aim herein 
was not a comparison in the context of effective-
ness and safety assessment between tranvenous 
and leadless pacemaker.
The first ten cases of Micra implantation were 
performed in the certificated Clinic. The introduc-
tion of a novel technology is usually accompanied 
by a period of learning in which operators develop 
and refine new skills until they achieve a “steady 
state” characterized by high efficiency and proce-
dural success with low complications. This is one 
limitation of the present study.
Conclusions
The presented registry of Micra implantation 
is the first single-center observational study in 
Poland. Early results from this and other clinical 
evaluations suggest that leadless pacing is effec-
tive, safe and could gain wider adoption particularly 
in patients with contraindications to conventional 
cardiac pacing. Further studies on periprocedural 
antithrombotic management in patients with indica-
tions to permanent anticoagulation are warranted. 
Hospitalization costs for individual patients varies 
over a large range. Diversity of costs is mainly at-
tributed to concomitant indications (e.g. infection), 
comorbidities (e.g. dialysis) and post-procedural 
complications (e.g. bleeding and hematoma).
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